Advanced HIV disease during the 'Treat All' era in Botswana.
Advanced HIV disease during the 'Treat All' era in Botswana.
复制标题
DOI:
10.1097/qad.0000000000002701
复制
发表时间:
2020-12-01
期刊:
影响因子:
--
通讯作者:
Hachaambwa L
中科院分区:
文献类型:
--
作者:
Vinikoor MJ;Hachaambwa L
HIV-1 infection is a potentially manageable chronic disease through early diagnosis, engagement in a model of chronic care, and sustained use of antiretroviral therapy (ART). In sub-Saharan Africa (SSA), where HIV prevalence is the highest, effective models of care have been established for ART delivery and HIV testing has become a ubiquitous intervention at health facilities, in the community, and even at home. HIV-related mortality and HIV incidence have been cut drastically over the past 15 years. In recent years, most countries have adopted ‘Treat all’, which is expected to accelerate control of the HIV epidemic. Unfortunately, advanced HIV disease, the phase of infection that is characterized by severe immunodeficiency and high incidence of life-threatening opportunistic infections, appears to be an enduring problem in SSA. Lebelonyane et al.[1] analyzed the prevalence, predictors, and outcomes advanced HIV disease in Botswana, which has been among the most ambitious in adopting evidence-based HIV treatment and prevention interventions, including ‘Treat all’, and was the first country in SSA to announce that it had achieved the 90--90--90 targets [2].Lebelonyane et al.[1] performed a secondary analysis of the Botswana Combination Prevention Project, an intervention that was implemented from October 2013 to March 2018, among adults (16--64-year-olds) across 15 communities. The intervention package included HIV testing campaigns, scale-up of medical male circumcision, universal ART regardless of CD4+ count, and enhanced linkage and retention in HIV care. People living with HIV (PLHIV), who were identified as not taking ART as they were either newly diagnosed or previously diagnosed but not currently on therapy, were linked to clinical care at the facility. Among those who linked to care, investigators described the proportion with advanced HIV disease, defined as CD4+ count 200 cells/μl or less, identified demographic and treatment-related risk factors, and described subsequent ART outcomes, in comparison to those with higher CD4+ counts. Data from children and younger adolescents were unfortunately not reported.